A Comparative Study on Intranasal Versus Intravenous Lorazepam in the Management of Acute Seizure in Children

Nandan Rudra1, Taraknath Ghosh2, Uttam Kumar Roy3

  • 1Kalna Subdivisional & Superspeciality Hospital, Purba Burdwan (West Bengal), India.

Folia Medica
|July 19, 2022
PubMed

Insights

Intranasal lorazepam is as effective and safe as intravenous lorazepam for treating acute childhood seizures. This study suggests intranasal lorazepam is a viable alternative for emergency seizure management in children.

Area of Science:

  • Pediatric Emergency Medicine
  • Clinical Pharmacology
  • Neurology

Background:

  • Acute seizures in children are medical emergencies often treated with benzodiazepines.
  • Intravenous lorazepam is a recommended first-line therapy, but intranasal administration lacks established guidelines in India.
  • Intranasal lorazepam offers potential advantages in ease of administration and home-based treatment initiation.

Purpose of the Study:

  • To compare the effectiveness and safety of intranasal versus intravenous lorazepam for acute seizures in children aged 5-12 years.
  • To evaluate intranasal lorazepam as a potential alternative to intravenous administration.

Main Methods:

  • An analytical observational cross-sectional study design was employed.
  • Patients with acute seizures received lorazepam via either the intravenous or intranasal route.
  • The formulation and dosage of lorazepam were consistent across both administration routes.

Main Results:

  • No statistically significant differences were observed in patient demographics (sex, age, weight) between the groups.
  • Seizure control within 10 minutes and persistent cessation of seizure activity were comparable between intranasal and intravenous lorazepam.
  • Safety parameters demonstrated no significant differences between the two administration routes.

Conclusions:

  • Intranasal lorazepam demonstrates comparable effectiveness and safety to intravenous lorazepam in managing acute childhood seizures.
  • Intranasal lorazepam presents a valuable alternative option for emergency seizure management in pediatric patients.
  • Further research may support broader adoption of intranasal lorazepam in clinical practice.
Abstract

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
191
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
686
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
801
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
428